Jane Street
CLDI icon

Jane Street’s Calidi Biotherapeutics CLDI Stock Holding History

Jane Street’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.31K Buy
34,802
+23,311
+203% +$17.5K ﹤0.01% 11319
2025
Q4 		$13.4K Buy
+11,491
New +$16.9K ﹤0.01% 10796
2025
Q1 		– Sell
-2,786
Closed -$38.5K – 9550
2024
Q4 		$38.5K Buy
+2,786
New +$52.2K ﹤0.01% 9036

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Jane Street's CLDI Position: Q1 2026 in Review

Jane Street increased its Calidi Biotherapeutics (CLDI) stake by 203% in Q1 2026, buying an estimated $17.5K and bringing the position to 34,802 shares worth $8.31K. The position accounts for ﹤0.01% of the portfolio, ranked #11319.

Jane Street first reported a position in CLDI in Q4 2024 and has held it in 3 quarters since. The position peaked at $38.5K in Q4 2024. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Jane Street held 34,802 shares of Calidi Biotherapeutics worth $8.31K as of Q1 2026.
  • Jane Street bought 23,311 Calidi Biotherapeutics shares in Q1 2026, an estimated $17.5K.
  • Calidi Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #11319 holding.
  • Jane Street first reported a position in Calidi Biotherapeutics in Q4 2024 and has held it in 3 quarters since.
  • Jane Street's Calidi Biotherapeutics position peaked at $38.5K in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.